

Xultophy (insulin degludec; liraglutide)

Prior Authorization Request Form

Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.

Xultophy (insulin degludec; liraglutide)

Prior Authorization Request Form

Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____

MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Type 2 diabetes <input type="checkbox"/> Other Diagnosis _____ ICD-10 Code(s): _____		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Clinical Information: Is the patient already taking the requested medication? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient received prior treatment with Soliqua (insulin glargine/lixisenatide)? <input type="checkbox"/> Yes <input type="checkbox"/> No Was the patient's most recent HgbA1c (within the past 6 months or prior to starting a GLP-1/insulin combination product) 7% or greater? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Copy of HgbA1c level required</i> Has the patient tried or is the patient currently receiving treatment with metformin? <input type="checkbox"/> Yes <input type="checkbox"/> No Is this patient's estimated GFR less than or equal to 45 mL/min/1.73 m ² ? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have advanced liver disease with at least one of the following? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, please select: <input type="checkbox"/> Ascites <input type="checkbox"/> Hepatic encephalopathy <input type="checkbox"/> Cirrhosis <input type="checkbox"/> Portal hypertension Has treatment with metformin been avoided due to lactic acidosis or elevated liver enzymes? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient currently taking any of the following medications? <input type="checkbox"/> Yes <input type="checkbox"/> No <ul style="list-style-type: none">• Kazano (alogliptin/metformin)• Glyxambi (empagliflozin/linagliptin)• Kombiglyze XR (saxagliptin/metformin)• Nesina (alogliptin)• Onglyza (saxagliptin)• Januvia (sitagliptin)• Oseni (alogliptin/pioglitazone)		

Xultophy (insulin degludec; liraglutide)

Prior Authorization Request Form

Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____

MEMBER'S FIRST NAME: _____

- Janumet/Janumet XR (sitagliptin/metformin)
- Tradjenta (linagliptin)
- Jentadueto/Jentadueto XR (linagliptin/metformin)
- QTERN (dapagloflozin/saxagliptin)
- Seglujan (ertugliflozin/sitagliptin)

If yes, will concomitant therapy with those agents be discontinued? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnoses are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201

P.O. Box 64811

St. Paul, MN 55164-0811